Primary IOL implantation in pediatric open globe injuries with active inflammation showed inferior visual outcomes compared ...

The FDA approved the Tecnis PureSee IOL, an extended depth of focus IOL for cataract surgery, according to a press release ...

The Conversation reports cataract surgery is safe and common, with over 90% achieving 20/20 vision, but patients need to ...

The TECNIS Odyssey IOL addresses a significant unmet need for cataract patients seeking greater spectacle independence., Bizz ...

The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...

Among children who underwent unilateral cataract removal in infancy, risk of glaucoma-related adverse events continues to increase with longer follow-up and is not associated with primary intraocular ...

Most people have a relative, friend or neighbor who has had to deal with a cataract. Nearly 24.5 million Americans age 40 or older are affected by cataracts, and it’s the leading cause of blindness ...

The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.

Johnson & Johnson (NYSE:JNJ) received FDA approval for its TECNIS PureSee IOL, an extended depth of focus intraocular lens for cataract patients. The lens is described as the first of its kind in the ...

FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...